Patents Assigned to Schwarz Pharma
-
Patent number: 8344176Abstract: The present disclosure relates to a process for the preparation of 2-(3 -diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol or its phenolic monoesters or salts thereof, characterized by the steps of a) reacting a compound of formula (II) with a mixture of a Grignard initiator and Mg in a solvent; b) optionally reducing the temperature of the Grignard reagent to a lower temperature than in step a), and reacting the resulting Grignard reagent with an excess of a carbonate in a solvent, to obtain a compound of formula (III) wherein A is a C1-C6 alkyl, and the further reacting the compound of formula (III) in a known manner to obtain the desired end product.Type: GrantFiled: May 26, 2007Date of Patent: January 1, 2013Assignee: Schwarz Pharma Ltd.Inventors: Roisin Browne, Michael Kilkelly
-
Publication number: 20100324144Abstract: The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.Type: ApplicationFiled: June 29, 2007Publication date: December 23, 2010Applicant: SCHWARZ PHARMA AGInventors: Cara Heers, Thomas Stoehr, Bettina Beyreuther
-
Publication number: 20100292499Abstract: The present disclosure relates to a process for the preparation of a compound of formula (I) wherein R is hydrogen, a formyl group, a straight, branched or cyclic C1-C6 alkylcarbonyl group or a phenylcarbonyl group, or a salt thereof, characterized by the steps of reacting a compound of formula (II) with a mixture of Grignard initiator and Mg in a solvent to form a Grignard reagent, reacting the Grignard reagent with paraformaldehyde or trioxane to obtain a compound of formula (III) and then further reacting the compound of formula (III) in a known manner to obtain a compound of formula (I) and optionally salt formation.Type: ApplicationFiled: June 5, 2007Publication date: November 18, 2010Applicant: SCHWARZ PHARMA LTD.Inventors: Seth C. Ennis, Cornelia Fuchs, Ralf Kanzler, Dean A. Johnson
-
Publication number: 20100273714Abstract: The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.Type: ApplicationFiled: June 15, 2007Publication date: October 28, 2010Applicant: SCHWARZ PHARMA AGInventor: Thomas Stoehr
-
Publication number: 20100174107Abstract: This disclosure relates to process for the preparation of a compound of formula (I) wherein R is hydrogen, a straight or branched C1-C6 alkyl-carbonyl group or a phenylcarbonyl group, or a salt thereof, comprising the following steps: a) adding to a suspension of Mg a compound of formula (II) R1(MgX)n—LiY wherein n is 1 or 2; R1 is an aromatic, aliphatic, carbocyclic or heterocyclic organic group having 1 to 24 carbon atoms; X and Y are independently selected from Cl, Br and I, b) reacting said reaction mixture with a suitable halogenated compound in a solvent to form a Grignard reagent, c) reacting said Grignard reagent with a suitable linear, branched or cyclic carbonate to obtain a compound of formula (TV) wherein A is a linear, branched or cyclic C1-C6 alkyl group, and preferably a methyl group, and then further reacting the compound of formula (IV) in a known manner to obtain a compound of formula (I) and optionally salt formation.Type: ApplicationFiled: June 4, 2007Publication date: July 8, 2010Applicant: SCHWARZ PHARMA LTD.Inventors: Seth C. Ennis, Bryan D. Kennedy
-
Publication number: 20100168459Abstract: The present invention provides a process for the production of a compound of formula (I) or a salt thereof, wherein R is hydrogen, a straight, branched or cyclic C1-C6 alkyl group or an aryl group which may optionally be substituted. This process comprises: (a) reacting a compound of formula (II), with a compound of formula (III), wherein R is as defined above and X is a leaving group, in the presence of N,N-di-isopropylethylamine.Type: ApplicationFiled: June 5, 2007Publication date: July 1, 2010Applicant: SCHWARZ PHARMA LTD.Inventors: Seth C. Ennis, Roland Drews, Claus Meese
-
Publication number: 20100130606Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: ApplicationFiled: January 22, 2010Publication date: May 27, 2010Applicant: SCHWARZ PHARMA AGInventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
-
Publication number: 20100099770Abstract: The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.Type: ApplicationFiled: December 21, 2009Publication date: April 22, 2010Applicant: SCHWARZ PHARMA AGInventor: Norma Selve
-
Patent number: 7687553Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.Type: GrantFiled: August 26, 2005Date of Patent: March 30, 2010Assignee: Schwarz Pharma AGInventors: Bettina Beyreuther, Thomas Stohr
-
Patent number: 7670621Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.Type: GrantFiled: April 3, 2004Date of Patent: March 2, 2010Assignee: Schwarz Pharma AGInventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
-
Publication number: 20100029543Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.Type: ApplicationFiled: October 12, 2009Publication date: February 4, 2010Applicant: SCHWARZ PHARMA AGInventors: Bettina Beyreuther, Thomas Stohr
-
Patent number: 7632859Abstract: By using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 in a iontophoretic device for the treatment of Parkinson's disease, it became possible to obtain a rotigotine flux across the human stratum corneum which was higher than the one previously obtained with conventional passive diffusion systems.Type: GrantFiled: November 17, 2003Date of Patent: December 15, 2009Assignee: Schwarz Pharma AGInventors: Gai Ling Li, Johanna Aaltje Bouwstra, Hans-Michael Wolff, Akhmad Karis Nugroho
-
Publication number: 20090306421Abstract: The present disclosure relates to a process for the preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol or its phenolic monoesters or salts thereof, characterized by the steps of a) reacting a compound of formula (II) with a mixture of a Grignard initiator and Mg in a solvent; b) optionally reducing the temperature of the Grignard reagent to a lower temperature than in step a), and reacting the resulting Grignard reagent with an excess of a carbonate in a solvent, to obtain a compound of formula (III) wherein A is a C1-C6 alkyl, and the further reacting the compound of formula (III) in a known manner to obtain the desired end product.Type: ApplicationFiled: May 26, 2007Publication date: December 10, 2009Applicant: SCHWARZ PHARMA LTD.Inventors: Roisin Browne, Michael Kilkelly
-
Publication number: 20090274761Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.Type: ApplicationFiled: April 2, 2009Publication date: November 5, 2009Applicant: SCHWARZ PHARMA AGInventors: Armin BREITENBACH, Claus MEESE, Hans-Michael WOLFF, Roland DREWS
-
Publication number: 20090192224Abstract: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.Type: ApplicationFiled: June 6, 2007Publication date: July 30, 2009Applicant: SCHWARZ PHARMA AGInventor: Claus Meese
-
Publication number: 20090117159Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.Type: ApplicationFiled: December 23, 2008Publication date: May 7, 2009Applicant: SCHWARZ PHARMA AGInventors: Hans-Jurgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
-
Publication number: 20090042981Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.Type: ApplicationFiled: April 17, 2008Publication date: February 12, 2009Applicant: SCHWARZ PHARMA AGInventors: Claus Meese, Bengt Sparf
-
Publication number: 20090036455Abstract: Novel substituted arylpiperazine derivatives with activity as 5-hydroxytryptamine 1A (5-HT1A) receptor subtype ligands, to their stereochemical isomers, methods of their preparation, and to their use and to pharmaceutical compositions containing them for the treatment of Parkinson disease, cerebral damage by thromboembolic ictus, craneoencephalic traumatisms, depression, migraine, pain, psychosis, anxiety disorders, aggressive disorders or urinary tract disorders.Type: ApplicationFiled: December 27, 2005Publication date: February 5, 2009Applicant: CEPA SCHWARZ PHARMA, S.L.Inventors: Maria Luz Lopez-Rodriguez, Bellinda Benhamu Salama
-
Publication number: 20090018198Abstract: The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies.Type: ApplicationFiled: September 18, 2008Publication date: January 15, 2009Applicant: Schwarz Pharma AGInventor: Thomas Stohr
-
Publication number: 20080287545Abstract: The present invention is directed to the use of a class of peptide compounds for the prophylaxis and treatment of chronic headache, particularly migraines.Type: ApplicationFiled: April 15, 2005Publication date: November 20, 2008Applicant: SCHWARZ PHARMA AGInventors: Dieter Scheller, Thomas Stohr